Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
646
datasets available to search
ShareScore release 0.9.0
Dataset results
646 results for “Clinical data”
Rearing pigs with play opportunities: viral load and clinical, behavioural, performance, and immune data
Open the record for dataset details and reuse information.
Data from: Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
Open the record for dataset details and reuse information.
Data from: Low levels of hypertension screening in HIV care clinics in rural Uganda: a mixed methods study
Open the record for dataset details and reuse information.
Leveraging a global, rederated, real-world data network to optimize investigator-initiated pediatric clinical trials: The TriNetX Pediatric Collaboratory Network
Open the record for dataset details and reuse information.
Data from: Implementation of a pediatric telemedicine and medication delivery service in a resource-limited setting: A pilot study for clinical safety and feasibility
Open the record for dataset details and reuse information.
Data from: Genetic variants and clinical indicators used to build nomogram model
Open the record for dataset details and reuse information.
Clinical trial generalizability assessment in the big data era: a review
Open the record for dataset details and reuse information.
Data from: Impact of explainable artificial intelligence assistance on clinical decision making of novice dental clinicians
Open the record for dataset details and reuse information.
Data from: Etiology of respiratory tract infections in the community and clinic in Ilorin, Nigeria
Open the record for dataset details and reuse information.
Data from: The clinical, histological, and genotypic spectrum of SEPN1-related myopathy: A case series
Open the record for dataset details and reuse information.
Data from: Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: A multicentre clinical study of two end-to-end commercial workflows
Open the record for dataset details and reuse information.
Data from: Photothermal-assisted antibacterial application of GO-Ag nanocomposites against clinical isolated MDR E. coli
Open the record for dataset details and reuse information.
Supplemental data from: Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial
Open the record for dataset details and reuse information.
Data from: Effect of mitochondrial oxidative stress on regulatory T cell manufacturing for clinical application in transplantation: Results from a pilot study
Open the record for dataset details and reuse information.
Data from: Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis.
<p>Absolute numbers of COVID-19 cases and deaths reported to date in the sub-Saharan Africa (SSA) region have been relatively low. As a result, there has been limited investigation into deceased cases in the region, as well as the impacts of different case management strategies. We detail demographic, epidemiological, and clinical information derived from publicly available information on deceased cases in SSA and, for cases in Burkina Faso, from aggregate records at the Center Hospitalier Universitaire de Tengandogo. Logistic regression was conducted on a synthetic case population to evaluate the adjusted odds of survival for patients receiving oxygen therapy or convalescent plasma, based on therapeutic effectiveness observed for other respiratory illnesses. Across SSA, deceased cases have been predominantly male and over 50 years of age. After adjustment for sex, age, and underlying conditions, the odds of mortality among cases in the synthetic population not receiving oxygen therapy was significantly higher than those receiving oxygen (OR: 2.07; 95%CI: 1.56-2.75). Cases receiving convalescent plasma had 50% reduced odds of mortality (95%CI: 0.24-0.93).<b> </b>Investment in sustainable oxygen therapy could reduce COVID-19 deaths in SSA. Ongoing investigation into convalescent plasma is warranted, as data on its effectiveness specifically in treating COVID-19 becomes available.</p>
Data from: Total Aβ42/Aβ40 ratio in plasma predict amyloid-PET status, independent of clinical AD diagnosis
Background: Research has focussed upon the identification of a blood-based biomarker to inform clinicians on the likelihood of Alzheimer's disease pathology prior to ordering the CSF and PET testing. Objective: To explore if the plasma total Aβ42/Aβ40 ratio is a reliable predictor of the amyloid-PET status we have explored the association between these two variables in a subset of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort. Methodology: Taking plasma samples at three separate time points, we assessed the total Aβ42/Aβ40 ratio in plasma (TP42/40) with regard to neocortical amyloid beta (Aβ) burden via PET SUVR, and investigated both association with Aβ-PET status and correlation (and agreement) with SUVR. Results: The TP42/40 plasma ratio was associated with PET status at all time points (p<0.013). Correlations with SUVR were similar across each time point, with Spearman's Rho reaching -0.64 (p<0.0001). Area under the curve (AUC) values were highly reproducible over time points, with values ranging from 0.880 at 36 months to 0.913 at 54 months. Assessing the healthy control (HC) group only, the same relationships were found. Conclusions: The current study demonstrates reproducibility of the plasma assay to discriminate between amyloid-PET positive and negative over three time points, which can help to substantially reducing the screening rate of failure (SRF) for clinical trials targeting pre-clinical or prodromal disease. Classification of evidence: This study provides Class II evidence that plasma total AB42/AB40 ratio is associated with neocortical amyloid burden as measured by PET SUVR.
Data from: Distinct epileptiform abnormalities are associated with clinical seizures in Alzheimer's disease
Objective: Examine the relationship between scalp EEG biomarkers of hyperexcitability in Alzheimer's disease (AD) and determine how these electrical biomarkers relate to the clinical expression of seizures in AD. Methods: In this cross-sectional study, we performed 24-hour ambulatory scalp EEGs on 43 cognitively normal elderly healthy controls (HC), 41 early-stage AD participants with no history or risk factors for epilepsy (AD-NoEp), and 15 early-stage AD participants with late-onset epilepsy related to AD (AD-Ep). Two epileptologists, blinded to diagnosis, visually reviewed all EEGs and annotated all potential epileptiform abnormalities. A panel of 9 epileptologists, blinded to diagnosis, was then surveyed to generate a consensus interpretation of epileptiform abnormalities in each EEG. Results: Epileptiform abnormalities were seen in 53% of AD-Ep, 22% of AD-NoEp, and 4.7% of HC participants. Specific features of epileptiform discharges, including high frequency, robust morphology, right temporal location, and occurrence during wakefulness and REM, were associated with clinical seizures in AD. Multiple electrical biomarkers concordantly demonstrated a pattern of left temporal lobe hyperexcitability in early stages of AD, whereas clinical seizures in AD were often associated with bi-temporal hyperexcitability. Frequent small sharp spikes were specifically associated with epileptiform EEGs and thus identified as a potential biomarker of hyperexcitability in AD. Conclusion: Epileptiform abnormalities are common in AD, but not all equivalent. Specific features of epileptiform discharges are associated with clinical seizures in AD. Given the difficulty recognizing clinical seizures in AD, these EEG features could provide guidance on which AD patients are at high risk for clinical seizures.
Data from: Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial
<p><strong>Background:</strong> High rates of patient attrition from care between HIV testing and antiretroviral therapy (ART) initiation have been documented in sub-Saharan Africa, contributing to persistently low CD4 cell counts at treatment initiation. One reason for this is that starting ART in many countries is a lengthy and burdensome process, imposing long waits and multiple clinic visits on patients. We estimated the effect on uptake of ART and viral suppression of an accelerated initiation algorithm that allowed treatment-eligible patients to be dispensed their first supply of antiretroviral medications on the day of their first HIV-related clinic visit.</p> <p><strong>Methods and Findings: </strong>RapIT was an unblinded randomized controlled trial of single-visit ART initiation in two public sector clinics in South Africa (a primary health clinic (PHC) and a hospital-based HIV clinic). Adult (≥18), non-pregnant patients receiving a positive HIV test or first treatment-eligible CD4 count were randomized to standard or rapid initiation. Rapid arm patients received a point-of-care (POC) CD4 count if needed; those ART-eligible received a POC TB test if symptomatic, POC blood tests, physical exam, education, counseling, and ARV dispensing. Standard arm patients followed standard clinic procedures (3-5 additional clinic visits over 2-4 weeks prior to ARV dispensing). Follow up was by record review only. The primary outcome was viral suppression, defined as initiated, retained in care, and suppressed (<=400 copies/ml) ≤ 10 months of study enrollment. Secondary outcomes included initiation of ART ≤ 90 days of study enrollment; retention in care; time to ART initiation; patient-level predictors of primary outcomes; prevalence of TB symptoms; and the feasibility and acceptability of the intervention. A survival analysis was conducted comparing attrition from care after ART initiation between the groups among those who initiated within 90 days. 377 patients were enrolled in the study between May 8, 2013 and August 29, 2014 (median CD4 count 210 cells/mm<sup>3</sup>). In the rapid arm, 119/187 patients (64%) initiated and were suppressed at 10 months, compared to 96/190 (51%) in the standard arm (RR 1.26 [1.05-1.50]. In the rapid arm 182/187 (97%) initiated ART ≤ 90 days, compared to 136/190 (72%) in the standard arm (relative risk [95% CI] 1.36 [1.24-1.49]. Among 318 patients who did initiate ART within 90 days, the hazard of attrition within the first 10 months did not differ between the treatment arms (HR 1.06; 95% CI 0.61-1.84). The study was limited by the small number of sites and small sample size and the generalizability of the results to other settings and to non-research conditions is uncertain.</p> <p><strong>Conclusions: </strong>Offering single-visit ART initiation to adult patients in South Africa increased uptake of ART by 36% and viral suppression by 26%. It should be considered for adoption in the public sector in Africa.</p>
Data from: Clinical correlation between erectile function and ejaculatory function in the Czech male population
Introduction The objective of this study is to determine whether there is any relationship between erectile function (EF) and ejaculatory function (EJF), with the aim of improving care protocols in the clinical practice. Materials and methods A total of 1004 Czech males between 15 and 84 years (42.77 ± 17.556 years) completed a sexual behavior questionnaire. A correlational, between-subjects design was used, where a 5-item abbreviated form of the International Index of Erectile Function (IIEF-5) was used to measure EF, which produces a value between 5 and 25. Values greater than 21 are considered as a normal function. EJF was measured using the Index of Premature Ejaculation (IPE). IPE has three domains (Control, Satisfaction and Distress) with scores from 0 to 100, higher ones are associated with a greater control and satisfaction, and lower anxiety, all related to the perception of ejaculation. A linear regression analysis was performed and a statistics model was proposed for each domain with EF as a dependent variable and the specific EF domain as a predictor. The Pearson correlation coefficient was also calculated for these variables. Results EF scale mean value was 19,44 ± 2,368, control domain mean value was 80,98 ± 18,032; sexual satisfaction domain mean value was 78,07 ± 21,454; and distress domain mean value was 74,85 ± 34,498. The results indicate that all linear regression models between EF and each of the domain of EJF and the Pearson coefficients (r) are statistically significant (p<0.05). Control r=0,478, p=.001, Satisfaction r=0,405, p=.001 and Distress r=0,324, p=.002. Conclusions Higher levels of EF are associated with a better control and sexual satisfaction, and less distress about ejaculation. This link should be considered for developing new clinical practice guidelines for erectile dysfunction and premature ejaculation.
Data from: Comparative analyses of clinical and environmental populations of Cryptococcus neoformans in Botswana
Cryptococcus neoformans var. grubii (Cng) is the most common cause of fungal meningitis, and its prevalence is highest in sub-Saharan Africa. Patients become infected by inhaling airborne spores or desiccated yeast cells from the environment, where the fungus thrives in avian droppings, trees and soil. To investigate the prevalence and population structure of Cng in southern Africa, we analysed isolates from 77 environmental samples and 64 patients. We detected significant genetic diversity among isolates and strong evidence of geographic structure at the local level. High proportions of isolates with the rare MATa allele were observed in both clinical and environmental isolates; however, the mating-type alleles were unevenly distributed among different subpopulations. Nearly equal proportions of the MATa and MATα mating types were observed among all clinical isolates and in one environmental subpopulation from the eastern part of Botswana. As previously reported, there was evidence of both clonality and recombination in different geographic areas. These results provide a foundation for subsequent genomewide association studies to identify genes and genotypes linked to pathogenicity in humans.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.